Matches in SemOpenAlex for { <https://semopenalex.org/work/W3088293821> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W3088293821 endingPage "22" @default.
- W3088293821 startingPage "22" @default.
- W3088293821 abstract "Background: In CARE-MS II (NCT00548405), 2 courses of alemtuzumab demonstrated significantly greater improvements on clinical outcomes vs SC IFNB-1a over 2 years (y) in patients (pts) with active RRMS and inadequate response to prior therapy. Alemtuzumab pts who were followed for a further 4 y in an extension study (NCT0090553) showed durable efficacy, even though most received no additional alemtuzumab or other disease-modifying therapy (DMT). In CARE-MS II, pts received 2 courses of alemtuzumab 12 mg/day (baseline: 5 days; 12 months [mo] later: 3 days); in the extension, pts could receive as-needed alemtuzumab retreatment (12 mg/day on 3 consecutive days; ≥12 mo after previous course for relapse or MRI activity) or another DMT (per investigator discretion). Pts completing the extension could enroll in the 5-y TOPAZ study (NCT02255656) for further long-term evaluation.Objectives: Evaluate efficacy and safety of alemtuzumab in CARE-MS II pts over 7 y.Methods: In TOPAZ, pts can receive alemtuzumab retreatment ≥12 mo after previous course or another DMT at any time (both per investigator discretion); MRI scans are done annually. Assessments included: annualized relapse rate (ARR); proportions of relapse-free pts; 6-mo confirmed disability worsening (CDW); 6-mo confirmed disability improvement (CDI); no evidence of disease activity (NEDA); adverse events (AEs).Results: 338/393 (86%) CARE-MS II alemtuzumab-treated pts who entered the extension remained on study until end of Y6. 336 then entered TOPAZ; 317 (94%) remained on study through Y7. Low ARR was maintained (0.14 at Y7). 87% of pts were relapse-free in Y7. Proportion of pts with stable or improved EDSS remained high (Y7: 73%). Through 7 y, 69% of pts were free of 6-mo CDW, 44% experienced 6-mo CDI, and the majority achieved NEDA in each year. These effects were achieved with 47% of pts receiving no further treatment (alemtuzumab or another DMT) after their initial 2 alemtuzumab courses. Incidences of most AEs, infusion-associated reactions, and infections decreased over time and were reduced vs the 2-y core study. Thyroid AE incidence peaked at Y3, then declined through Y7.Conclusion: Clinical efficacy of alemtuzumab was durable for 7 y in pts who had inadequate response to prior therapy, despite 47% receiving no further treatment since the initial 2 alemtuzumab courses. The majority of pts maintained low ARR, were relapse-free, showed stabilized or improved disability, and achieved NEDA in each year." @default.
- W3088293821 created "2020-10-01" @default.
- W3088293821 creator A5025462803 @default.
- W3088293821 creator A5028669492 @default.
- W3088293821 creator A5034380106 @default.
- W3088293821 creator A5038384028 @default.
- W3088293821 creator A5049456235 @default.
- W3088293821 creator A5050636465 @default.
- W3088293821 creator A5055135931 @default.
- W3088293821 creator A5063615479 @default.
- W3088293821 creator A5065646936 @default.
- W3088293821 creator A5069727178 @default.
- W3088293821 creator A5078067575 @default.
- W3088293821 creator A5081885557 @default.
- W3088293821 creator A5083385630 @default.
- W3088293821 creator A5088301395 @default.
- W3088293821 date "2018-02-01" @default.
- W3088293821 modified "2023-09-22" @default.
- W3088293821 title "Durable Improvements in Relapse and Disability Outcomes over 7 Years with Alemtuzumab in CARE-MS II Patients: Results from the TOPAZ Study" @default.
- W3088293821 hasPublicationYear "2018" @default.
- W3088293821 type Work @default.
- W3088293821 sameAs 3088293821 @default.
- W3088293821 citedByCount "0" @default.
- W3088293821 crossrefType "journal-article" @default.
- W3088293821 hasAuthorship W3088293821A5025462803 @default.
- W3088293821 hasAuthorship W3088293821A5028669492 @default.
- W3088293821 hasAuthorship W3088293821A5034380106 @default.
- W3088293821 hasAuthorship W3088293821A5038384028 @default.
- W3088293821 hasAuthorship W3088293821A5049456235 @default.
- W3088293821 hasAuthorship W3088293821A5050636465 @default.
- W3088293821 hasAuthorship W3088293821A5055135931 @default.
- W3088293821 hasAuthorship W3088293821A5063615479 @default.
- W3088293821 hasAuthorship W3088293821A5065646936 @default.
- W3088293821 hasAuthorship W3088293821A5069727178 @default.
- W3088293821 hasAuthorship W3088293821A5078067575 @default.
- W3088293821 hasAuthorship W3088293821A5081885557 @default.
- W3088293821 hasAuthorship W3088293821A5083385630 @default.
- W3088293821 hasAuthorship W3088293821A5088301395 @default.
- W3088293821 hasConcept C126322002 @default.
- W3088293821 hasConcept C187212893 @default.
- W3088293821 hasConcept C197934379 @default.
- W3088293821 hasConcept C2779015954 @default.
- W3088293821 hasConcept C2911091166 @default.
- W3088293821 hasConcept C71924100 @default.
- W3088293821 hasConceptScore W3088293821C126322002 @default.
- W3088293821 hasConceptScore W3088293821C187212893 @default.
- W3088293821 hasConceptScore W3088293821C197934379 @default.
- W3088293821 hasConceptScore W3088293821C2779015954 @default.
- W3088293821 hasConceptScore W3088293821C2911091166 @default.
- W3088293821 hasConceptScore W3088293821C71924100 @default.
- W3088293821 hasOpenAccess W3088293821 @default.
- W3088293821 hasRelatedWork W2046838396 @default.
- W3088293821 hasRelatedWork W2302686310 @default.
- W3088293821 hasRelatedWork W2354547847 @default.
- W3088293821 hasRelatedWork W2522202632 @default.
- W3088293821 hasRelatedWork W2549078628 @default.
- W3088293821 hasRelatedWork W2555136035 @default.
- W3088293821 hasRelatedWork W2555940313 @default.
- W3088293821 hasRelatedWork W2559481507 @default.
- W3088293821 hasRelatedWork W2564225780 @default.
- W3088293821 hasRelatedWork W2569885932 @default.
- W3088293821 hasRelatedWork W2574325656 @default.
- W3088293821 hasRelatedWork W2575361154 @default.
- W3088293821 hasRelatedWork W2587110037 @default.
- W3088293821 hasRelatedWork W2597156185 @default.
- W3088293821 hasRelatedWork W2771532908 @default.
- W3088293821 hasRelatedWork W2911431721 @default.
- W3088293821 hasRelatedWork W2979296342 @default.
- W3088293821 hasRelatedWork W2982255223 @default.
- W3088293821 hasRelatedWork W3196876910 @default.
- W3088293821 hasRelatedWork W3209431811 @default.
- W3088293821 hasVolume "24" @default.
- W3088293821 isParatext "false" @default.
- W3088293821 isRetracted "false" @default.
- W3088293821 magId "3088293821" @default.
- W3088293821 workType "article" @default.